CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model.
Neidemire-Colley L, Khanal S, Braunreiter KM, Gao Y, Kumar R, Snyder KJ, Weber MA, Surana S, Toirov O, Karunasiri M, Duszynski ME, Chi M, Malik P, Kalyan S, Chan WK, Naeimi Kararoudi M, Choe HK, Garzon R, Ranganathan P.
Neidemire-Colley L, et al. Among authors: naeimi kararoudi m.
Blood Adv. 2024 Feb 27;8(4):947-958. doi: 10.1182/bloodadvances.2023010570.
Blood Adv. 2024.
PMID: 38181781
Free PMC article.